Q3 EPS Estimates for Beta Bionics Decreased by Analyst

Beta Bionics, Inc. (NASDAQ:BBNX) – Analysts at Leerink Partnrs decreased their Q3 2025 earnings per share estimates for shares of Beta Bionics in a report issued on Tuesday, July 29th. Leerink Partnrs analyst M. Kratky now expects that the company will post earnings of ($0.43) per share for the quarter, down from their prior forecast of ($0.42). Leerink Partnrs also issued estimates for Beta Bionics’ Q4 2025 earnings at ($0.38) EPS, FY2025 earnings at ($1.60) EPS, FY2026 earnings at ($2.03) EPS, FY2027 earnings at ($2.35) EPS, FY2028 earnings at ($1.38) EPS and FY2029 earnings at ($0.90) EPS.

A number of other analysts also recently issued reports on the company. Lake Street Capital assumed coverage on Beta Bionics in a research note on Thursday, June 12th. They issued a “buy” rating and a $30.00 price objective on the stock. Truist Financial lifted their price objective on Beta Bionics from $18.00 to $21.00 and gave the stock a “buy” rating in a research note on Wednesday. Robert W. Baird set a $17.00 target price on Beta Bionics and gave the company a “neutral” rating in a research report on Wednesday. The Goldman Sachs Group started coverage on Beta Bionics in a research report on Friday, May 30th. They set a “neutral” rating and a $16.00 target price on the stock. Finally, Wolfe Research started coverage on Beta Bionics in a research report on Friday, May 30th. They set an “outperform” rating and a $20.00 target price on the stock. Four investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $22.56.

Beta Bionics Stock Performance

NASDAQ:BBNX opened at $16.40 on Friday. Beta Bionics has a 1 year low of $8.89 and a 1 year high of $24.50. The business has a 50 day moving average price of $15.71.

Beta Bionics (NASDAQ:BBNX) last released its quarterly earnings data on Tuesday, July 29th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.12. The firm had revenue of $23.24 million during the quarter, compared to the consensus estimate of $19.73 million.

Hedge Funds Weigh In On Beta Bionics

A number of large investors have recently bought and sold shares of BBNX. Strs Ohio purchased a new position in Beta Bionics during the 1st quarter valued at $29,000. CWM LLC purchased a new position in Beta Bionics during the 2nd quarter valued at $58,000. Corebridge Financial Inc. purchased a new position in Beta Bionics during the 1st quarter valued at $79,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Beta Bionics during the 1st quarter valued at $95,000. Finally, MetLife Investment Management LLC purchased a new position in Beta Bionics during the 1st quarter valued at $102,000.

Insider Buying and Selling at Beta Bionics

In related news, CFO Stephen Feider sold 1,497 shares of the business’s stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $17.89, for a total transaction of $26,781.33. Following the completion of the transaction, the chief financial officer owned 45,503 shares in the company, valued at $814,048.67. The trade was a 3.19% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last 90 days, insiders sold 4,519 shares of company stock worth $80,845.

Beta Bionics Company Profile

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.